Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Golen, K. L.
Right arrow Articles by Merajver, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Golen, K. L.
Right arrow Articles by Merajver, S. D.
Clinical Cancer Research Vol. 5, 2511-2519, September 1999
© 1999 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

A Novel Putative Low-Affinity Insulin-like Growth Factor-binding Protein, LIBC (Lost in Inflammatory Breast Cancer), and RhoC GTPase Correlate with the Inflammatory Breast Cancer Phenotype1

Kenneth L. van Golen, Seena Davies, Zhi Fen Wu, YunFang Wang, Corazon D. Bucana, Holly Root, Settara Chandrasekharappa, Myla Strawderman, Stephen P. Ethier and Sofia D. Merajver2

Departments of Internal Medicine, Division of Hematology and Oncology [K. L. v. G., S. D., Z. F. W., S. D. M.] and Radiation Oncology [S. P. E.], The University of Michigan Health System, Ann Arbor, Michigan 48109; Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [Y. W., C. D. B.] National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892-4431 [H. R., S. C.]; University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 [K. L. v. G., S. D., Z. F. W., M. S., S. P. E., S. D. M.]

Inflammatory breast cancer is a rapidly growing, distinct form of locally advanced breast cancer that carries a guarded prognosis. To identify the genes that contribute to this aggressive phenotype, we compared under- and overexpressed sequences in an inflammatory breast tumor cell line with those of actively replicating normal human mammary epithelial cell lines using differential display. Of the 17 transcripts isolated and characterized from these experiments, overexpression of RhoC GTPase and loss of expression of a novel gene on 6q22, LIBC (lost in inflammatory breast cancer), were highly correlated (P < 0.0095 and P < 0.0013, respectively) with the inflammatory phenotype when a panel of archival inflammatory breast cancers was compared with noninflammatory stage III breast cancers by in situ hybridization. This study suggests two new molecular markers specific for inflammatory breast cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. J. Hayes, D. Thomas, A. Emmons, T. J. Giordano, and C. G. Kleer
Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast
Clin. Cancer Res., July 1, 2008; 14(13): 4038 - 4044.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. Huang, Y. Zhang, S. Varambally, A. M. Chinnaiyan, M. Banerjee, S. D. Merajver, and C. G. Kleer
Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1
Am. J. Pathol., April 1, 2008; 172(4): 893 - 904.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, P. LoRusso, D. P. Lombardi, S. Ben Ahmed, D. L. Citrin, M. L. DeSilvio, et al.
Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy
J. Clin. Oncol., March 1, 2008; 26(7): 1066 - 1072.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff
Locally Advanced and Inflammatory Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
C. R. Evelyn, S. M. Wade, Q. Wang, M. Wu, J. A. Iniguez-Lluhi, S. D. Merajver, and R. R. Neubig
CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling
Mol. Cancer Ther., August 1, 2007; 6(8): 2249 - 2260.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. R. Davies, G. Watkins, R. E. Mansel, and W. G. Jiang
Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer
Ann. Surg. Oncol., June 1, 2007; 14(6): 1909 - 1918.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
T. Vargo-Gogola, B. M. Heckman, E. J. Gunther, L. A. Chodosh, and J. M. Rosen
P190-B Rho GTPase-Activating Protein Overexpression Disrupts Ductal Morphogenesis and Induces Hyperplastic Lesions in the Developing Mammary Gland
Mol. Endocrinol., June 1, 2006; 20(6): 1391 - 1405.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. J. Van Laere, I. Van der Auwera, G. G. Van den Eynden, H. J. Elst, J. Weyler, A. L. Harris, P. van Dam, E. A. Van Marck, P. B. Vermeulen, and L. Y. Dirix
Nuclear Factor-{kappa}B Signature of Inflammatory Breast Cancer by cDNA Microarray Validated by Quantitative Real-time Reverse Transcription-PCR, Immunohistochemistry, and Nuclear Factor-{kappa}B DNA-Binding.
Clin. Cancer Res., June 1, 2006; 12(11): 3249 - 3256.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Hakuma, I. Kinoshita, Y. Shimizu, K. Yamazaki, K. Yoshida, M. Nishimura, and H. Dosaka-Akita
E1AF/PEA3 Activates the Rho/Rho-Associated Kinase Pathway to Increase the Malignancy Potential of Non-Small-Cell Lung Cancer Cells
Cancer Res., December 1, 2005; 65(23): 10776 - 10782.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Pan, L. W. Bao, C. G. Kleer, M. S. Sabel, K. A. Griffith, T. N. Teknos, and S. D. Merajver
Protein Kinase C{varepsilon} Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy
Cancer Res., September 15, 2005; 65(18): 8366 - 8371.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
A. Hakem, O. Sanchez-Sweatman, A. You-Ten, G. Duncan, A. Wakeham, R. Khokha, and T. W. Mak
RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis
Genes & Dev., September 1, 2005; 19(17): 1974 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. M. Jacobsen, S. A. Schittone, J. K. Richer, and K. B. Horwitz
Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology
Mol. Endocrinol., March 1, 2005; 19(3): 574 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Interv.Home page
T. M. Seasholtz and J. H. Brown
RHO SIGNALING in Vascular Diseases
Mol. Interv., December 1, 2004; 4(6): 348 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, V. Nasser, B. Loriod, J. Camerlo, R. Tagett, C. Tarpin, G. Houvenaeghel, et al.
Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy
Cancer Res., December 1, 2004; 64(23): 8558 - 8565.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Simpson, A. S. Dugan, and A. M. Mercurio
Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma
Cancer Res., December 1, 2004; 64(23): 8694 - 8701.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Bieche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, and R. Lidereau
Molecular Profiling of Inflammatory Breast Cancer: Identification of a Poor-Prognosis Gene Expression Signature
Clin. Cancer Res., October 15, 2004; 10(20): 6789 - 6795.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. G. Jiang, G. Watkins, J. Lane, G. H. Cunnick, A. Douglas-Jones, K. Mokbel, and R. E. Mansel
Prognostic Value of Rho GTPases and Rho Guanine Nucleotide Dissociation Inhibitors in Human Breast Cancers
Clin. Cancer Res., December 15, 2003; 9(17): 6432 - 6440.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. H. Giordano
Update on Locally Advanced Breast Cancer
Oncologist, December 1, 2003; 8(6): 521 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. J. McCarthy, X. Yang, I. R. Linnoila, M. J. Merino, S. M. Hewitt, A. L. Parr, S. Paik, S. M. Steinberg, D. P. Hartmann, N. Mourali, et al.
Microvessel Density, Expression of Estrogen Receptor {alpha}, MIB-1, p53, and c-erbB-2 in Inflammatory Breast Cancer
Clin. Cancer Res., December 1, 2002; 8(12): 3857 - 3862.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Tsutsumi, S. K. Gupta, V. Hogan, J. G. Collard, and A. Raz
Activation of Small GTPase Rho Is Required for Autocrine Motility Factor Signaling
Cancer Res., August 1, 2002; 62(15): 4484 - 4490.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. L. van Golen, L. Bao, M. M. DiVito, Z. Wu, G. C. Prendergast, and S. D. Merajver
Reversion of RhoC GTPase-induced Inflammatory Breast Cancer Phenotype by Treatment with a Farnesyl Transferase Inhibitor
Mol. Cancer Ther., June 1, 2002; 1(8): 575 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. G. Kleer, K. L. van Golen, Y. Zhang, Z.-F. Wu, M. A. Rubin, and S. D. Merajver
Characterization of RhoC Expression in Benign and Malignant Breast Disease : A Potential New Marker for Small Breast Carcinomas with Metastatic Ability
Am. J. Pathol., February 1, 2002; 160(2): 579 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. L. van Golen, Z.-F. Wu, X. T. Qiao, L. W. Bao, and S. D. Merajver
RhoC GTPase, a Novel Transforming Oncogene for Human Mammary Epithelial Cells That Partially Recapitulates the Inflammatory Breast Cancer Phenotype
Cancer Res., October 1, 2000; 60(20): 5832 - 5838.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.